MarketsandMarkets conferences are proud to announce its Nanotechnologies in Drug Delivery Congress on the 27 – 28 April 2015 in London, United Kingdom. Bringing together 150+ industry experts from the nanomedicine market in which drug delivery technologies alone are expected to reach $224 billion by 2017.
The role of technology in the delivery of medicine guarantees revolutionary advances with measuring the size of the particles in nanometer ranges; this detailed analysis has helped improve the efficiency of drug delivery on a large scale. The application of drug delivery has facilitated advanced treatment of cancer, cardiovascular, pulmonary, genetic, and infectious diseases and considers assessment and review procedures involved in the development of gene-based pharmaceuticals.
Bringing together 25+ expert speakers from academia and industry, the two day program will examine key concerns in drug delivery including Nanotechnology drug enabled drug delivery in HIV therapy, siRNA, and blood protein analysis as well as exploring nanotechnology in medicine design.
The conference will provide an interactive networking platform to highlight the innovations in one of the fastest growing drug delivery fields through keynote presentations, interactive panel discussions, case studies and an exhibition area where leading industry providers will showcase their products and services.
Successfully Sourcing New Technologies from both Academia and the Industry
• Using nanoscale fabrication techniques to investigate the device design with manageable surface properties as well as devices capable of functioning as biosensors and stimuli-sensitive delivery platforms
• Magneto-electric nanoparticles are being developed as vehicles for delivering and releasing the anti-HIV drug AZTTP into the brain
• Sugar-sensitive nanoparticles that release glucose can revolutionize diabetes treatment
Exclusive Pre-event Speaker Interview:
Prof. Andrew Owen
Professor of Molecular and Clinical Pharmacology, University of Liverpool, Chair, British Society for Nano medicine, Liverpool - UK
Nanotechnology-based HIV drug delivery has attracted recent attention within academia with many technologies in early stage evaluation for improving oral bioavailability or targeting HIV-infected cells and tissues. Interest has been significantly accelerated recently by the entry of long-acting Nano formulations into human trials. These Nano formulations developed by Janssen Pharmaceuticals and ViiV Healthcare are able to sustain therapeutic concentrations in blood for over 1 month from a single intramuscular depot injection.
Modern antiretroviral therapy has significantly improved morbidity and mortality but patient adherence to medication is an on-going issue that frequently results in treatment failure. Also, many antiretroviral drugs exhibit poor bioavailability and adverse drug reactions are common. The ability to administer drugs monthly rather than daily at lower overall doses may mitigate issues with adherence and pill fatigue, which will hopefully translate to improved patient outcomes.
To register for conference click here.